Product Description
Although p38_ is upregulated in the lungs of COPD patients, AZD7624, an isoform-specific inhaled p38 MAPK inhibitor, failed to show any benefit in patients with COPD. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877500/)
Mechanisms of Action: MAPK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Asthma
Phase 1: Chronic Obstructive Pulmonary Disease|Inflammation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12617001587392p |
CBR-sCAR19-3001 | N/A |
Not yet recruiting |
Acute Respiratory Distress Syndrome|Down Syndrome|Turner Syndrome |
2018-09-28 |
|||
NCT01817855 |
D2550C00002 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2014-10-01 |
2019-03-19 |
Treatments |
|
NCT01937338 |
D2550C00004 | P1 |
Completed |
Inflammation |
2014-04-01 |
2019-03-19 |
Treatments |
|
NCT01754844 |
D2550C00001 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2013-08-01 |
2019-03-19 |
Treatments |
|
NCT02753764 |
HS-2995 | P2 |
Completed |
Asthma |
2019-02-25 |
2019-08-22 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT02238483 |
D2550C00005 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2016-04-04 |
2019-03-20 |
Treatments |
|
2014-001053-16 |
2014-001053-16 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2016-01-07 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|